Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2.

Publication Type:

Journal Article


Sexually transmitted diseases, Volume 37, Issue 5, p.290-7 (2010)


2010, Center-Authored Paper, Clinical Research Division, Epidemiology Core Facility, Female, Herpes Genitalis, Herpes Simplex Virus Vaccines, Herpesvirus 2, Human, Humans, KENYA, Male, Mass Vaccination, Models, Statistical, Models, Theoretical, Population Groups, Research Trials Office Core Facility - Biostatistics Service, Risk Factors, Shared Resources, Vaccine and Infectious Disease Division, Virus Shedding


The continuation of developing Herpes simplex virus type-2 (HSV-2) prophylactic vaccines requires parallel mathematical modeling to quantify the effect on the population of these vaccines.